2N Pharma ApS: Financial statements 2021
CVR: 41169303
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
2N Pharma ApS (CVR 41169303) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 1,538,094 and a net result of DKK -318,464 compared with DKK -187,930 the year before. That is an increase of 357.9% compared with the year before. Equity in the 2021 report amounted to DKK 8,862,836. The solvency ratio was 52.8%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 1,538,094
- Profit/Loss
- DKK -318,464
- Equity
- DKK 8,862,836
- Total Assets
- DKK 16,778,307
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 1.5 mio. | -318 t. | 8.9 mio. | 5 |
| 2020 | - | 336 t. | -188 t. | -148 t. | 1 |
Official annual report
Find more companies like 2N Pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
As of July 6, 2021, 2N Pharma Holding ApS is registered as an owner of 2N Pharma ApS with an ownership share of 100%.
2N Pharma ApS has published its interim report for the period February 14, 2020 – December 31, 2020.
As of June 28, 2021, Preben Bruun-Nyzell has joined the board of directors of 2N Pharma ApS.
As of June 28, 2021, Josephus Dirk Vestergaard Nieland has joined the board of directors of 2N Pharma ApS.
As of June 28, 2021, Alex Leech has joined the board of directors of 2N Pharma ApS.
As of June 28, 2021, John Kemp has joined the board of directors of 2N Pharma ApS.
As of June 28, 2021, Preben Bruun-Nyzell is registered as adm. dir. of 2N Pharma ApS.
As of June 27, 2021, Preben Bruun-Nyzell has stepped down as director of 2N Pharma ApS.
About 2N Pharma ApS
2N Pharma ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2020. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company is owned by 2N Pharma Holding ApS. According to the 2024 annual report, the company had an average of 3 employees. In 2024, the company reported a gross profit of DKK 1,077,483 and a net result of DKK -396,379 compared with DKK -346,799 the year before. Equity in the 2024 report amounted to DKK 10,304,869.